The Tel Aviv Stock Exchange is set to team with the NASDAQ later this month for an investor conference focusing on life science industries.
The conference, to be held at the Times Square NASDAQ building in New York, will include executives of ten participating Israeli biomed firms. It is intended to bring together leading TASE and NASDAQ-listed Israeli biomed companies together with U.S. investors specializing in life science investments.
A similar previous effort attracted dozens of American investors and analysts covering the field.
“We view broadening the exposure of Israel's biomed companies among foreign investors as one of our primary functions,” said TASE CEO Esther Levanon. “This conference, held in conjunction with NASDAQ, underscores the strategic cooperation between our two exchanges and is but one of the measures taken by TASE to promote awareness of Israeli technology industries in Israel and abroad.”
At present, close to 60 biomed companies are listed on the Tel Aviv Stock Exchange. The conference is expected to expose foreign investors to the vast potential of such firms.
Israeli companies who will be taking part in the conference on May 17 include: Aposense, BioLineRx, Clal Biotechnology, Compugen, Evogene, Itamar Medical, PhotoMedex, Pluristem Therapeutics, Prolor Biotech, and Protalix Biotherapeutics.